HUAWEI
During MWC Barcelona 2023, Huawei will be meeting with operators, industry partners, and other key opinion leaders from around the world to discuss "GUIDE to the Intelligent World". Together, they will look at how to use the GUIDE business blueprint to lay the foundation for 5.5G and build on the success of 5G for even greater prosperity in an intelligent world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006057/en/
Huawei's Hall 1 exhibition booth at MWC Barcelona 2023 (Photo: Huawei)
Huawei’s main exhibition booth in MWC Barcelona's Hall 1 is designed around the concept of “Intelligent Future, Full of Hope”. At the booth, Huawei painted a picture of an era fueled by the digital economy and defined by collaboration that is more vibrant and full of unlimited possibilities. At the event, Huawei is also showcasing its latest products and solutions that deliver ultimate 5G experiences, premium and intelligent ultra-broadband connectivity, digital and intelligent transformation, and their Green 1-2-3 solution. Huawei's offerings show a clear commitment to innovating for the 5.5G era, creating value for customers, and stimulating the digital economy.
By the end of 2022, 5G had already proven to be a global commercial success, with over a billion mobile users connecting with 5G. Leading operators in China, South Korea, Switzerland, Finland, and Kuwait have already achieved 5G user penetration rates of more than 30%, and more than 30% of their traffic comes from 5G.
According to Ookla's latest 5G City Benchmark Report, Huawei has played an important part in 5G network construction in all of the top 10 cities among the world's 40 representative 5G-enabled cities. It's important to note that 5G performance results in these 10 cities show that the 5G networks constructed by Huawei offer the best experience.
Following on from Huawei's concept of "Striding Towards the 5.5G Era" that was proposed in July 2022, Huawei is highlighting the five major characteristics of the 5.5G era: 10 Gbps experiences, full-scenario interconnection, integrated sensing and communication, L4 autonomous driving networks, and green ICT. Leading global operators, standards organizations, and industry ecosystem partners are coming together to promote innovation and exploration for this 5.5G era, as it will create more new applications and business opportunities.
Ongoing and robust investment into ICT infrastructure directly spurs growth within the digital economy. A third-party report shows that, as new networks evolve from one generation to another, this effect will be further amplified by 15%. Looking towards the future, we believe the GUIDE business blueprint that combines both 5G and 5.5G clearly lays out how ICT evolution will progress and bring about greater value.
Together with our customers and partners, we will continue to innovate, building intelligent connectivity and redefining computing. This collaboration on innovation will create even greater value for the ICT industry and make the industry as a whole more resilient and prosperous.
Huawei’s Enterprise division is also hosting their own event at MWC 2023, themed “Leading Digital Infrastructure for New Value Together”, where they will launch more than 50 innovative products and solutions for global customers. Highlights here include their Intelligent Simplified Campus Network Solution, a series of innovative data center solutions, and business strategies for small- and medium-sized enterprises (SMEs).
In the device field, Huawei is showcasing their new HUAWEI Mate 50 series, HUAWEI WATCH Buds, HUAWEI WATCH GT Cyber, that come packed with new innovation in areas like mobile imaging, fitness and health, and smart office.
MWC Barcelona 2023 runs from February 27 to March 2 in Barcelona, Spain. Huawei showcases its products and solutions at stand 1H50 in Fira Gran Via Hall 1. Together with global operators, industry professionals, and opinion leaders, we dive into topics such as 5G business success, 5.5G opportunities, green development, digital transformation, and our vision of using the GUIDE business blueprint to lay the foundation for 5.5G and build on the success of 5G for even greater prosperity. For more information, please visit: https://carrier.huawei.com/en/events/mwc2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006057/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom